The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Plethora Solutions Holdings Plc

10 Feb 2016 11:35

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: HARGREAVE HALE LIMITED (for Discretionary Clients)
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

PLETHORA SOLUTIONS HOLDINGS PLC
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A
(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

09 FEBRUARY 2016
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

NO

If YES, specify which:

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: ORDINARY 1p

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 8,070,000 0.9802
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

8,070,000 0.9802

NOTE: On 05/02/2016 166,667 ordinary shares were transferred in by a discretionary client, which took the total discretionary holdings from 0.9802% to 1.0004%. The subsequent sale of those same shares on 09/02/2016 is the reason for this Form 8.3 disclosure.

Class of relevant security: WARRANTS 2019

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 838,889 0.8294
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

838,889 0.8294

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
ORDINARY SALE 166,667 2.7p

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit
NONE

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit
NONE

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)
NONE

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 10 FEBRUARY 2016
Contact name: DAVID CLUEIT

HARGREAVE HALE LTD

Telephone number: 01253 754739

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160210005675/en/

Copyright Business Wire 2016

Date   Source Headline
17th Nov 20107:00 amRNSChange of Adviser
10th Nov 20102:27 pmRNSHolding in Company
7th Sep 20107:00 amRNSHalf Yearly Report
29th Jul 20102:27 pmRNSHolding(s) in Company
23rd Jul 201010:55 amRNSHolding(s) in Company
19th Jul 20107:00 amRNSNew Product Launch
13th Jul 20107:00 amRNSPre-close Trading Update
30th Jun 20107:00 amRNSTerm Loan Agreement
10th Jun 201012:06 pmRNSLTIP Awards
2nd Jun 20107:00 amRNSAmerican Urological Association Showcase
27th May 20109:27 amRNSResult of AGM
17th May 20107:00 amRNSCommercial Update - The Urology Company
6th May 20107:00 amRNSAnnual Report and Accounts
5th May 20107:00 amRNSIssue of Equity
12th Apr 20107:00 amRNSExclusive Distribution Agreement
9th Mar 20107:00 amRNSPreliminary Results
24th Feb 20103:31 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSNotice of Results
19th Jan 20107:00 amRNSPre-Close Trading Update
14th Dec 20095:23 pmRNSHolding(s) in Company
7th Dec 200911:23 amRNSResult of EGM
30th Nov 20097:00 amRNSExclusive License and Distribution Agreement
23rd Nov 20097:00 amRNSExclusive License and Distribution Agreement
19th Nov 20094:23 pmRNSDirector/PDMR Shareholding
18th Nov 20097:23 amRNSPlacing and Convertible Loan Note
30th Sep 20097:00 amRNSClinical Update re: PSD506
17th Sep 20097:00 amRNSInterim Results
7th Aug 20094:42 pmRNSHolding(s) in Company
5th Aug 200910:42 amRNSHolding(s) in Company
29th Jul 20097:00 amRNSFinal Phase III Pivotal Trial Results PSD502
16th Jul 20097:00 amRNSPSD503 Update - Evaluation and Option Agreement
25th Jun 20091:57 pmRNSAGM Statement and Trading Update
15th Jun 20093:57 pmRNSHolding(s) in Company
29th May 20093:34 pmRNSAnnual Report and Accounts and AGM Notice
26th May 20097:05 amRNSDirectorate Change
26th May 20097:00 amRNSGlobal Agreement, Restructuring and Final Results
1st Apr 20097:00 amRNSUpdate re: PSD502
19th Feb 20097:00 amRNSDirectorate Change
18th Feb 20099:24 amRNSClinical Update PSD502
16th Feb 200911:31 amRNSLoan Agreement and US License Amendment
16th Feb 200911:26 amRNSResult of General Meeting
22nd Jan 20097:00 amRNSFunding Update and Notice of GM
23rd Dec 20084:17 pmRNSHolding(s) in Company
18th Dec 200811:55 amRNSHolding(s) in Company
11th Dec 20089:12 amRNSHolding(s) in Company
8th Dec 20087:00 amRNSIssue of Equity
8th Dec 20087:00 amRNSClinical Update: PSD502
14th Nov 20087:00 amRNSHolding(s) in Company
14th Nov 20087:00 amRNSErecAid Study Results
7th Nov 20087:00 amRNSPhase III European Clinical Trial Results PSD502

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.